Advertisement

Journal of Inherited Metabolic Disease

, Volume 16, Issue 1, pp 127–134 | Cite as

The effect of lovastatin on very low-density lipoprotein apolipoprotein B production by the liver in familial combined hyperlipidaemia

  • J. A. Cortner
  • M. J. Bennett
  • N. -A. Le
  • P. M. Coates
Article

Summary

Overproduction of very low-density lipoprotein apolipoprotein B by the liver is a metabolic marker for familial combined hyperlipidaemia, a common inherited disorder of lipoprotein metabolism. Four subjects with familial combined hyperlipidaemia had rates of apolipoprotein B production which were 2–7 times normal, using a protocol in which [15N]nglycine was used to label newly synthesized hepatic proteins. Following 4–6 months of therapy with lovastatin, very low-density lipoprotein apolipoprotein B production in all four subjects had returned to the normal range. This demonstrates that lovastatin, an inhibitor of cholesterol biosynthesis, acts also to reduce the apparent production rate of apolipoprotein B by the liver.

Keywords

Public Health Cholesterol Internal Medicine Production Rate Lovastatin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Arad Y, Ramakrishnan R, Ginsberg HN (1990) Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: Implications for the pathophysiology of apoB production.J Lipid Res 30: 567–582.Google Scholar
  2. Arad Y, Ramakrishnan R, Ginsberg HN (1992) Effects of lovastatin therapy on very-low density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: Evidence for reduced assembly and secretion of triglyceride rich lipoproteins.Metabolism 41: 487–493.Google Scholar
  3. Babirak SP, Iverius P-H, Fujimoto WY, Brunzell JD (1989) Detection and characterization of the heterozygote state for lipoprotein lipase deficiency.Arteriosclerosis 9: 326–334.Google Scholar
  4. Baginsky ML (1981) Measurement of lipoprotein lipase and hepatic triglyceride lipase in human postheparin plasma.Methods Enzymol 72: 325–338.Google Scholar
  5. Bilheimer DW, Grundy SM, Brown MS, Goldstein JL (1983) Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes.Proc Natl Acad Sci USA 80: 4124–4128.Google Scholar
  6. BMDP (1985)Statistical Software Manual. Berkeley: University of California Press.Google Scholar
  7. Chait A, Albers JJ, Brunzell JD (1980) Very low density lipoprotein overproduction in genetic forms of hypertriglyceridaemia.Eur J Clin Invest 10: 17–22.Google Scholar
  8. Cortner JA, Coates PM, Gallagher PR (1990) Prevalence and expression of familial combined hyperlipidemia in childhood.J Pediatr 116: 514–519.Google Scholar
  9. Cortner JA, Coates PM, Bennett MJ, Cryer DR, Le N-A (1991) Familial combined hyperlipidaemia: Use of stable isotopes to demonstrate overproduction of very low-density lipoprotein apolipoprotein B by the liver.J Inher Metab Dis 14: 915–922.Google Scholar
  10. Cortner, JA, Le N-A, Coates PM, Bennett MJ, Cryer DR (1992) Determinants of fasting plasma triglyceride levels: Metabolism of hepatic and intestinal lipoproteins.Eur J Clin Invest 22: 158–165.Google Scholar
  11. Cryer DR, Matsushima T, Marsh JB, Yudkoff M, Coates PM, Cortner JA (1986) Direct measurement of apolipoprotein B synthesis in human very low density lipoprotein using stable isotopes and mass spectrometry.J Lipid Res 27: 508–516.Google Scholar
  12. East CD, Bilheimer W, Grundy SM (1988) Combination drug therapy for familial combined hyperlipidemia.Ann Intern Med 109: 25–32.Google Scholar
  13. Endo A, Kurodo M, Tsujita G (1976) ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced byPenicillium citrinum.J. Antibiot 29: 1346–1348.Google Scholar
  14. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of plasma low density lipoprotein cholesterol concentration without use of the preparative ultracentrifuge.Clin Chem 18: 499–502.Google Scholar
  15. Ginsberg HN, Le N-A, Short MP, Ramakrishnan R, Desnick RJ (1987) Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease and lovastatin: Implications for regulation of apolipoprotein B synthesis.J Clin Invest 80: 1692–1697.Google Scholar
  16. Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG (1973) Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, familial combined hyperlipidemia.J Clin Invest 52: 1544–1568.Google Scholar
  17. Grundy SM, Vega GL (1985) Influence of mevinolin on metabolism of low density lipoproteins in primary moderate hypercholesterolemia.J Lipid Res 26: 1464–1475.Google Scholar
  18. Grundy SM, Chait A, Brunzell JD (1987) Meeting summary: Familial combined hyperlipidemia workshop.Arteriosclerosis 7: 203–207.Google Scholar
  19. Havel RJ, Hunninghake DB, Illingworth DR et al (1987) Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia.Ann Intern Med 107: 609–615.Google Scholar
  20. Janus CD, Nicoll AM, Turner PR, Magill P, Lewis B (1980) Kinetic basis of the primary hyperlipidaemias: Studies of apolipoprotein B turnover in genetically defined subjects.Eur J Clin Invest 10: 161–172.Google Scholar
  21. Kesaniemi YA, Vega GL, Grundy SM (1982) Kinetics of apolipoprotein B in normal and hyperlipidemic man: Review of current data. In Berman M, Grundy SM, Howard BV, eds.Lipoprotein Kinetics and Modeling. New York: Academic Press, 181–205.Google Scholar
  22. Khan B, Wilcox HG, Heimberg M (1989) Cholesterol is required for secretion of very low density lipoprotein by rat liver.Biochem J 258: 807–816.Google Scholar
  23. Kissebah AH, Alfarsi S, Adams PW (1981) Integrated regulation of very low density lipoprotein triglyceride and apolipoprotein-B kinetics in man: Normolipidemic subjects, familial hypertriglyceridemia and familial combined hyperlipidemia.Metabolism 30: 856–868.Google Scholar
  24. Lipid Research Clinics (1980)Population Studies Data Book, Vol 1. The prevalence study. Bethesda, MD: National Institutes of Health publication no. 8:1528.Google Scholar
  25. Matsushima T, Cryer DR, Winkler KE, Marsh JB, Cortner JA (1989) Measurement of apolipoprotein B synthesis in perfused rat liver using stable isotopes:15N-Hippurate as a measure of the intracellular15N-glycine precursor enrichment.J Lipid Res 30: 841–846.Google Scholar
  26. Nikkila E, Aro A (1973) Family study of serum lipids and lipoproteins in coronary heart disease.Lancet 1: 954–959.Google Scholar
  27. Rose HG, Kranz PM, Weinstock J, Juliano J, Haft JI (1973) Inheritance of combined hyperlipoproteinemia: Evidence of a new lipoprotein phenotype.Am J Med 54: 148–160.Google Scholar
  28. Vega GL, Grundy SM (1991) Influence of lovastatin therapy on metabolism of low density lipoproteins in mixed hyperlipidemia.J Intern Med 230: 341–349.Google Scholar
  29. Vega GL, Krauss RM, Grundy SM (1990) Pravastatin therapy in primary moderate hypercholesteraemia: changes in metabolism of apolipoprotein B-containing lipoproteins.J Intern Med 227: 81–94.Google Scholar
  30. Warnick GR, Benderson J, Albers JJ (1983) Dextran sulfate-Mg2+ precipitation procedure for quantitation of high density lipoprotein cholesterol. In Cooper GR, ed.Select Methods of Clinical Chemistry. Washington, DC: AACC Press, 91–99.Google Scholar

Copyright information

© Society for the Study of Inborn Errors of Metabolism and Kluwer Academic Publishers 1993

Authors and Affiliations

  • J. A. Cortner
    • 1
    • 2
  • M. J. Bennett
    • 3
  • N. -A. Le
    • 4
  • P. M. Coates
    • 1
    • 2
  1. 1.Lipid-Heart Research CenterThe Children's Hospital of PhiladelphiaPhiladelphiaUSA
  2. 2.Department of PediatricsUniversity of PennsylvaniaPhiladelphiaUSA
  3. 3.Metabolic Disease CenterBaylor University Medical CenterDallasUSA
  4. 4.Division of Arteriosclerosis and Lipid Metabolism, Department of MedicineEmory UniversityAtlantaUSA

Personalised recommendations